InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Completes Phase 1 Trial for MS Treatment, Reports Positive Safety Results
February 26, 2025
Quantum BioPharma (NASDAQ: QNTM) announced the successful completion of its Phase 1 clinical trial evaluating Lucid-21-302 (“Lucid-MS”), a first-in-class neuroprotective compound for multiple sclerosis. A final safety review committee meeting confirmed that Lucid-MS was well-tolerated with no serious adverse events. The drug, designed to stabilize the myelin sheath and protect against demyelination, showed promising safety results, […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Engages MZ Group for Investor Relations Strategy
February 11, 2025
Quantum BioPharma (NASDAQ: QNTM) has retained MZHCI, an MZ Group company, to lead its investor relations and financial communications efforts. The initiative aims to enhance the company’s visibility within the investment community, emphasizing its portfolio focused on brain disorders and alcohol health. MZ will highlight Quantum BioPharma’s products, including unbuzzd™ and rekvry™, which address excessive […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Engages Enterprise Canada, Empire Market Ventures for PR, Investor Awareness
February 10, 2025
Quantum BioPharma (NASDAQ: QNTM) has retained Enterprise Canada Inc. and Empire Market Ventures, LLC to lead its public relations and investor awareness efforts. Enterprise, engaged indefinitely, will develop the company’s media strategy, while Empire, engaged for three months starting Feb. 7, 2025, will focus on investor marketing and outreach. The company highlighted progress on its key […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Licensee Celly Nutrition Pursues $10M Capital Raise and U.S. IPO
February 6, 2025
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Celly Nutrition Corp., has engaged a leading New York investment bank to raise up to $10 million and explore an initial public offering on a major U.S. exchange. Quantum BioPharma holds a 25.71% stake in Celly Nutrition and receives a 7% royalty on sales of its product, unbuzzd™, […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Positive Clinical Trial Results for unbuzzd™
February 4, 2025
Quantum BioPharma (NASDAQ: QNTM) announced the successful completion of a clinical trial demonstrating that its dietary supplement, unbuzzd™, significantly accelerates alcohol metabolism and reduces symptoms of intoxication and hangovers. The double-blind, placebo-controlled study showed that unbuzzd™ lowered blood alcohol concentration by over 40% faster within 30 minutes compared to placebo, while improving alertness and stabilizing […]
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
January 28, 2025
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company committed to developing innovative solutions to address neurodegenerative and metabolic disorders, as well as alcohol misuse. The company’s portfolio includes groundbreaking therapeutic candidates such as Lucid-MS, a patented compound targeting multiple sclerosis, and consumer-focused products like unbuzzd(TM), a novel alcohol detoxification beverage. Through strategic investments […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Announces Completion of Name Change, Begins Trading Under New Symbol
August 15, 2024
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), formerly FSD Pharma Inc., a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has finalized its previously announced name change and consolidation. According to the announcement, the company’s class B subordinate voting shares began trading today under the new ticker symbol QNTM. In […]
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Shareholders Approve Plans for Share Consolidation, Name Change
August 12, 2024
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is planning to consolidate its issued and outstanding class A multiple voting shares and class B subordinate voting shares. The company also has announced a planned name change to Quantum BioPharma Ltd, with […]